• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Medtronic supply woes buoy insulin device makers

August 22, 2017 By Brad Perriello

diabetesShare prices for makers of insulin management devices got a bump today after Medtronic (NYSE:MDT) reported today that supply problems pushed sales down -1% for its diabetes division.

The Fridley, Minn.-based company, which released its fiscal 2018 first-quarter results this morning, posted diabetes revenues of $449 million for the three months ended July 28. The decline was driven by strong demand for Medtronic’s CGM-enabled insulin pumps, especially the MiniMed 670G hybrid closed-loop device.

“The additional demand has resulted in fulfillment prioritization to the existing installed based, including MiniMed 670G priority access program customers, affecting sales of sensor-augmented pumps to new customers in the near-term. In addition, strong customer enrollment in its priority access program is also temporarily affecting revenue growth,” Medtronic said.

“The strength of our diversification and solid underlying performance of our businesses, combined with the stable growth of our end markets, enabled us to manage the impact of a global IT system disruption and temporary diabetes sensor supply constraint,” added chairman & CEO Omar Ishrak. “While these temporary issues had affected first-quarter revenue growth, we continued to drive operating margin expansion.

That news, and lower-than-expected sales for the entire company, pushed MDT shares down -2.2% to $81.71 apiece today, but buoyed shares of rival diabetes management companies including Dexcom (NSDQ:DXCM), Tandem Diabetes Care (NSDQ:TNDM) and Insulet (NSDQ:PODD).

DXCM shares were up 4.1% to $76.03 each, TNDM’s stock rose 8.3% to $70.1¢ per share and PODD hit $57.44 for a 3.0% gain  in late-morning activity.

Filed Under: Diabetes, Featured, Wall Street Beat Tagged With: DexCom Inc., Insulet, Medtronic, Tandem Diabetes Care

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS